Debiopharm Acquires Wee-1 Kinase Inhibitor Program from Almac Discovery

Swiss biopharma Debiopharm International negotiated global rights to Almac Discovery’s Wee-1 kinase inhibitor program. The deal gives Debiopharm exclusive rights to Almac Discovery’s Wee-1 patent portfolio and associated IP, in return for an undisclosed upfront payment, plus future development and commercial milestone payments, and sales royalties.Almac Discovery has developed and optimized a series of oral, selective inhibitors of Wee-1 kinase, a regulator of the G2 checkpoint. Comm